Theravance Biopharma, Inc. Financing Cash Flow
Theravance Biopharma, Inc. (TBPH) reported Financing Cash Flow of -$6.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$967.00K.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$5.58M.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$1.49M.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$400.00K.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$3.25M.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$2.50M.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$198.93M.
- Theravance Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$758.81M, a 926.05% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$967.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$6.54M 10-Q · filed 2026-08-11 | -$8.04M derived: sum of 3 quarters · filed 2026-08-11 | -$8.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$5.58M 10-Q · filed 2026-05-07 | -$7.07M derived: sum of 2 quarters · filed 2026-05-07 | -$7.47M derived: sum of 3 quarters · filed 2026-05-07 | -$7.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$1.89M derived: sum of 2 quarters · filed 2026-03-23 | -$2.39M derived: sum of 3 quarters · filed 2026-08-11 | -$3.25M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$903.00K derived: sum of 2 quarters · filed 2026-08-11 | -$1.76M 10-Q · filed 2025-11-12 | -$2.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$503.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.36M 10-Q · filed 2026-08-11 | -$1.72M derived: sum of 3 quarters · filed 2026-08-11 | -$2.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$854.00K 10-Q · filed 2026-05-07 | -$1.22M derived: sum of 2 quarters · filed 2026-05-07 | -$1.59M derived: sum of 3 quarters · filed 2026-05-07 | -$1.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$737.00K derived: sum of 2 quarters · filed 2026-03-23 | -$781.00K derived: sum of 3 quarters · filed 2026-03-23 | -$2.50M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$372.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$416.00K derived: sum of 2 quarters · filed 2025-11-12 | -$2.13M 10-Q · filed 2025-11-12 | -$32.74M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.76M 10-Q · filed 2025-08-13 | -$32.37M derived: sum of 3 quarters · filed 2025-08-13 | -$63.77M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$1.72M 10-Q · filed 2025-05-12 | -$32.33M derived: sum of 2 quarters · filed 2025-05-12 | -$63.73M derived: sum of 3 quarters · filed 2025-05-12 | -$144.41M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$30.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$62.01M derived: sum of 2 quarters · filed 2025-03-07 | -$142.69M derived: sum of 3 quarters · filed 2025-03-07 | -$198.93M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$31.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$112.08M derived: sum of 2 quarters · filed 2024-11-14 | -$168.32M 10-Q · filed 2024-11-14 | -$203.80M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$80.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$136.92M 10-Q · filed 2024-08-08 | -$172.39M derived: sum of 3 quarters · filed 2024-08-08 | -$894.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$56.24M 10-Q · filed 2024-05-15 | -$91.71M derived: sum of 2 quarters · filed 2024-05-15 | -$813.74M derived: sum of 3 quarters · filed 2024-05-15 | -$813.60M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$35.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$757.50M derived: sum of 2 quarters · filed 2024-03-01 | -$757.36M derived: sum of 3 quarters · filed 2024-03-01 | -$758.81M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$722.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$721.89M derived: sum of 2 quarters · filed 2023-11-09 | -$723.33M 10-Q · filed 2023-11-09 | -$723.18M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.31M 10-Q · filed 2023-08-09 | -$1.16M derived: sum of 3 quarters · filed 2023-08-09 | -$3.44M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.45M 10-Q · filed 2023-05-10 | -$1.30M derived: sum of 2 quarters · filed 2023-05-10 | -$3.58M derived: sum of 3 quarters · filed 2023-05-10 | $101.70M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$2.14M derived: sum of 2 quarters · filed 2023-03-01 | $103.15M derived: sum of 3 quarters · filed 2023-03-01 | $91.86M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $103.00M derived: sum of 2 quarters · filed 2022-11-09 | $91.71M 10-Q · filed 2022-11-09 | $92.45M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $105.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $94.00M 10-Q · filed 2022-08-08 | $94.74M derived: sum of 3 quarters · filed 2023-03-01 | $93.78M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$11.29M 10-Q · filed 2022-05-06 | -$10.54M derived: sum of 2 quarters · filed 2023-03-01 | -$11.51M derived: sum of 3 quarters · filed 2023-03-01 | -$9.63M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $743.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$220.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.65M derived: sum of 3 quarters · filed 2023-03-01 | $263.08M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$963.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $910.00K derived: sum of 2 quarters · filed 2021-11-08 | $262.34M 10-Q · filed 2021-11-08 | $260.80M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $263.31M 10-Q · filed 2021-08-05 | $261.76M derived: sum of 3 quarters · filed 2022-02-28 | $261.63M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $261.43M 10-Q · filed 2021-05-06 | $259.89M derived: sum of 2 quarters · filed 2022-02-28 | $259.75M derived: sum of 3 quarters · filed 2022-02-28 | $264.16M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$1.68M derived: sum of 2 quarters · filed 2022-02-28 | $2.72M derived: sum of 3 quarters · filed 2022-02-28 | $1.29M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $4.27M derived: sum of 2 quarters · filed 2020-11-09 | $2.83M 10-Q · filed 2020-11-09 | $232.44M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.97M 10-Q · filed 2020-08-10 | $232.57M derived: sum of 3 quarters · filed 2021-02-26 | $232.25M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$1.43M 10-Q · filed 2020-05-08 | $228.17M derived: sum of 2 quarters · filed 2021-02-26 | $227.85M derived: sum of 3 quarters · filed 2021-02-26 | $225.45M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $229.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $229.28M derived: sum of 2 quarters · filed 2021-02-26 | $226.88M derived: sum of 3 quarters · filed 2021-02-26 | $225.20M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$322.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$2.72M derived: sum of 2 quarters · filed 2019-11-08 | -$4.40M 10-Q · filed 2019-11-08 | -$3.77M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$4.08M 10-Q · filed 2019-08-05 | -$3.45M derived: sum of 3 quarters · filed 2020-02-27 | -$4.24M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$1.68M 10-Q · filed 2019-05-10 | -$1.05M derived: sum of 2 quarters · filed 2020-02-27 | -$1.84M derived: sum of 3 quarters · filed 2020-02-27 | $1.19M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $631.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$158.00K derived: sum of 2 quarters · filed 2020-02-27 | $2.87M derived: sum of 3 quarters · filed 2020-02-27 | $1.66M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$789.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.24M derived: sum of 2 quarters · filed 2018-11-08 | $1.02M 10-Q · filed 2018-11-08 | $333.48M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $1.81M 10-Q · filed 2018-08-02 | $334.27M derived: sum of 3 quarters · filed 2019-02-28 | $334.75M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$1.22M 10-Q · filed 2018-05-09 | $331.24M derived: sum of 2 quarters · filed 2019-02-28 | $331.72M derived: sum of 3 quarters · filed 2019-02-28 | |
| 2016-12-31 | $332.45M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $332.94M derived: sum of 2 quarters · filed 2019-02-28 | $479.23M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $481.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $146.77M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $146.29M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $81.31M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |